Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13852 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Aaron Koenig und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sage Therapeutics, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Huntington Disease, Receptors, N-Methyl-D-Aspartate, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sage Therapeutics, Inc, Sage Therapeutics.
Abstract (Originalsprache)
N‐methyl‐D‐aspartate receptor (NMDAR)‐positive allosteric modulators (PAMs) represent a potential therapeutic strategy for cognitive impairment in disorders associated with NMDAR hypofunction, including Huntington's disease (HD) and Alzheimer's disease. Dalzanemdor (SAGE‐718) is a novel, investigational NMDAR PAM being evaluated for the potential treatment of cognitive impairment in these disorders. We report first‐in‐human, phase I, double‐blind, dose‐finding studies to assess the safety, tolerability, and clinical pharmacology of dalzanemdor. A single‐ascending dose study (dalzanemdor 0.35, 0.75, 1.5, or 3.0 mg vs. placebo) was conducted in healthy participants and included food effects. A multiple‐ascending dose study (14 days) was conducted in healthy participants (dalzanemdor 0.5 or 1.0 mg vs. placebo) and HD participants (open‐label dalzanemdor 1.0 mg) and included exploratory pharmacodynamics on cognitive performance. Dalzanemdor was generally well tolerated with no adverse events leading to discontinuation. Dalzanemdor exhibited pharmacokinetic parameters appropriate for once‐daily dosing. Following single and multiple doses in healthy participants, median terminal half‐life was 8–118 h, and the median time to reach maximum plasma concentration was 4–7 h. Exposures were dose‐proportional after single dose (6–46 ng/mL) and more than dose‐proportional after multiple doses (6–41 ng/mL). With multiple dosing, a steady state was achieved after 11 days in healthy participants and 13 days in HD participants. Dalzanemdor exposure decreased slightly with food. In HD participants, results suggest that dalzanemdor may improve cognitive performance on tests of executive function. These results support continued clinical development of dalzanemdor for the potential treatment of cognitive impairment in disorders of NMDAR hypofunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sage Therapeutics, Inc, Cambridge, Massachusetts, USA.
ORCID-Profile: Jeff Wald
Förderung
- Sage Therapeutics, Inc
- Sage Therapeutics
Zitieren
APA
Koenig, A., Lewis, M., Wald, J., Li, S., Varoglu, M., Dai, J., Sankoh, A., Paumier, K., Doherty, J., & Quirk, M. (2024). Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease. Clinical and Translational Science. https://doi.org/10.1111/cts.13852
Vancouver
Koenig A, Lewis M, Wald J, Li S, Varoglu M, Dai J, et al. Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease. Clinical and Translational Science. 2024. doi:10.1111/cts.13852
BibTeX
@article{Koenig2024,
author = {Koenig, Aaron and Lewis, Michael and Wald, Jeff and Li, Sigui and Varoglu, Mustafa and Dai, Jing and Sankoh, Abdul and Paumier, Katrina and Doherty, James and Quirk, Mike},
title = {Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13852}
}
EUVIMED